Risk factors

4D Molecular Therapeutics (FDMT) risk factors

Item 1A of every 4D Molecular Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.

Open FDMT in Gloom →
4D Molecular Therapeutics' chart, financials and news, free in your browser.Open FDMT in Gloom →
  • FY2025 10-K risk factors
    85 risks

    Late-stage gene-therapy development remains unproven, with no approved products or product revenue.

    Filed Mar 18, 2026